Further investigation revealed that DcR3 is correlated with favorable clinical features in Metastasis 0 (M0) and stage I/II CRC patients, suggesting it may act as a suppressive factor in CRC. The gene discussed is TNFRSF6B; the disease is colorectal carcinoma.